Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis

Journal of the Formosan Medical Association

Volumn 113, Issue 11, 2014, Pages 833-838

  Chen, Kuan Hao ^a,b   Liu, Hsi Che ^b,c   Liang, Der Cherng ^b,c   Hou, Jen Yin ^a,b   Huang, Ting Huan ^b   Chang, Ching Yi ^b   Yeh, Ting Chi ^b,c  

^a NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c MACKAY MEDICAL COLLEGE   (Taiwan)

Author keywords

Acute myeloid leukemia; Chemotherapy; Children; Hyperleukocytosis; Leukapheresis

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; MIXED LINEAGE LEUKEMIA PROTEIN; RASBURICASE; URIC ACID; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; BONE MARROW BIOPSY; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CHILD; CHILDHOOD LEUKEMIA; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; HYPERLEUKOCYTOSIS; HYPERURICEMIA; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; INFANT; KIDNEY FAILURE; LEUKAPHERESIS; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOCYTE DISORDER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RESPIRATORY DISTRESS; RETINA HEMORRHAGE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URIC ACID BLOOD LEVEL; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTOSIS; NEWBORN; PRESCHOOL CHILD; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKAPHERESIS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MORBIDITY; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84922059365     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2014.01.006     Document Type: Article

References (26)

1. Ganzel C., Becker J., Mintz P.D., Lazarus H.M., Rowe J.M. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 2012, 26:117-122.
2. Stucki A., Rivier A.S., Gikic M., Monai N., Schapira M., Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001, 97:2121-2129.
3. Liang D.C., Chan T.T., Lin K.H., Lin D.T., Lu M.Y., Chen S.H., et al. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia 2006, 20:136-141.
4. Yeh T.C., Liu H.C., Wang L.Y., Chen S.H., Lin W.Y., Liang D.C. The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan. J Pediatr Hematol Oncol 2007, 29:826-831.
5. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625.
6. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:460-462.
7. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991, 78:325-329.
8. Liang D.C., Shih L.Y., Yang C.P., Hung I.J., Chen S.H., Liu H.C. Molecular analysis of fusion transcripts in childhood acute myeloid leukemia in Taiwan. Med Pediatr Oncol 2001, 37:555-556.
9. Inaba H., Fan Y., Pounds S., Geiger T.L., Rubnitz J.E., Ribeiro R.C., et al. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer 2008, 113:522-529.
10. Creutzig U., Zimmermann M., Reinhardt D., Dworzak M., Stary J., Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004, 22:4384-4393.
11. Lichtman M.A. Rheology of leukocytes, leukocyte suspensions, and blood in leukemia. Possible relationship to clinical manifestations. J Clin Invest 1973, 52:350-358.
12. Lichtman M.A., Rowe J.M. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 1982, 60:279-283.
13. Novotny J.R., Nückel H., Dührsen U. Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia. Eur J Haematol 2006, 76:299-308.
14. Thiébaut A., Thomas X., Belhabri A., Anglaret B., Archimbaud E. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol 2000, 79:501-506.
15. Powell B.L., Gregory B.W., Evans J.K., White J.C., Lyerly E.S., Chorley H.M., et al. Leukapheresis induced changes in cell cycle distribution and nucleoside transporters in patients with untreated acute myeloid leukemia. Leukemia 1991, 5:1037-1042.
16. Kotelnikov V.M., Kasatkina V.V., Dultsina S.M., Sarytcheva T.G., Kalinin N.N., Kovaleva L.G., et al. Effects of cytapheresis on cell cycle distribution of peripheral blood and bone marrow cells in some hematological malignancies. Leuk Res 1987, 11:397-403.
17. Zarkovic M., Kwaan H.C. Correction of hyperviscosity by apheresis. Semin Thromb Hemost 2003, 29:535-542.
18. Porcu P., Danielson C.F., Orazi A., Heerema N.A., Gabig T.G., McCarthy L.J. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol 1997, 98:433-436.
19. De Santis G.C., de Oliveira L.C., Romano L.G., Prado Bde Almeida P., Simoes B.P., Rego E.M., et al. Therapeutic leukapheresis in patients with leukostasis secondary to acute myelogenous leukemia. J Clin Apher 2011, 26:181-185.
20. Giles F.J., Shen Y., Kantarjian H.M., Korbling M.J., O'Brien S., Anderlini P., et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long-term survival. Leuk Lymphoma 2001, 42:67-73.
21. Bug G., Anargyrou K., Tonn T., Bialleck H., Seifried E., Hoelzer D., et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion 2007, 47:1843-1850.
22. Chang M.C., Chen T.Y., Tang J.L., Lan Y.J., Chao T.Y., Chiu C.F., et al. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. Am J Hematol 2007, 82:976-980.
23. Wang L.Y., Shih L.Y., Chang H., Jou S.T., Lin K.H., Yeh T.C., et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol 2006, 115:35-38.
24. Coiffier B., Altman A., Pui C.H., Younes A., Cairo M.S. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008, 26:2767-2778.
25. Dutcher J.P., Schiffer C.A., Wiernik P.H. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol 1987, 5:1364-1372.
26. Meshinchi S., Woods W.G., Stirewalt D.L., Sweetser D.A., Buckley J.D., Tjoa T.K., et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001, 97:89-94.